Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trials

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
Volume 11
Issue 3

Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.

Cirrus Pharmaceuticals, a Kemwell Company, has announced that it is ready to launch services for manufacturing cGMP materials for early-phase clinical trials in a new suite at its Raleigh-Durham, NC site.

The company offers development and manufacturing capabilities for niche dosage forms. The company will manufacture metered dose inhalers (MDI) on its Pamasol pressure filling line in batch sizes up to 25L. One- and two-step filling as well as cold filling for suspension and solution MDIs will be offered.

Other services include dry powder filling in capsules for dry powder inhalers, and manufacture of nasal solutions, suspensions, and powders. Clinical manufacturing of other dosage forms that will be offered from the site are topicals, oral solids, and oral liquids.

Source: Cirrus Pharmaceuticals, a Kemwell Company

 

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Related Content